Ivermectin: Could Population-Wide Distribution Have Prevented China’s Recent Mass COVID Outbreak?
China’s state-run medicare program recently failed to reach an agreement with Pfizer to import more Paxlovid, claiming the COVID-19 treatment drug is too expensive. This is despite the drug being offered to the state at a reduced rate in comparison
Read More